525P Final analysis of the JACCRO CC-16: Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to anti-EGFR antibody.

MLA

Sugiyama, K., et al. “525P Final Analysis of the JACCRO CC-16: Ramucirumab plus FOLFIRI for RAS Wild-Type MCRC Refractory to Anti-EGFR Antibody.” Annals of Oncology, vol. 35, Sept. 2024, p. S442. EBSCOhost, https://doi.org/10.1016/j.annonc.2024.08.594.

APA

Sugiyama, K., Yasui, H., Nakamura, M., Sagawa, T., Kawai, T., Kataoka, K., Manaka, D., Akazawa, N., Okuno, T., Shimura, T., Shiozawa, M., Sunakawa, Y., Ota, H., Kotaka, M., Okuyama, H., Okita, Y., Takeuchi, M., Ichikawa, W., Fujii, M., & Tsuji, A. (2024). 525P Final analysis of the JACCRO CC-16: Ramucirumab plus FOLFIRI for RAS wild-type mCRC refractory to anti-EGFR antibody. Annals of Oncology, 35, S442. https://doi.org/10.1016/j.annonc.2024.08.594

Chicago

Sugiyama, K., H. Yasui, M. Nakamura, T. Sagawa, T. Kawai, K. Kataoka, D. Manaka, et al. 2024. “525P Final Analysis of the JACCRO CC-16: Ramucirumab plus FOLFIRI for RAS Wild-Type MCRC Refractory to Anti-EGFR Antibody.” Annals of Oncology 35 (September): S442. doi:10.1016/j.annonc.2024.08.594.